D-Pharm Appoints Dr. Peter Lewis as Chairman of the Board.REHOVOT, Israel--(BW HealthWire)--Nov. 24, 1997--D-Pharm Ltd. announced today that Dr. Peter Lewis has been appointed Chairman of the Board of Directors. Dr. Lewis was formerly Director of Research & Development and a Main Board Director at British Biotech British Biotech was a British based biotech company. British Biotechnology Limited was founded in 1986 by former G D Searle managers Keith McCullagh and Brian Richards, [1] plc. During five years at British Biotech, Dr. Lewis took several new products into clinical evaluation clinical evaluation Medtalk An evaluation of whether a Pt has symptoms of a disease, is responding to treatment, or is having adverse reactions to therapy and played an active role in the flotation of British Biotech on the London Stock Exchange London Stock Exchange London marketplace for securities. It was formed in 1773 by a group of stockbrokers who had been doing business informally in local coffeehouses. . Previously, Dr. Lewis served as Vice President for Product Development at Marion Merrell Dow Inc. where he was responsible for development of all new pharmaceutical products worldwide. His knowledge of clinical therapeutics and expertise in satisfying the regulatory requirements of major countries led to the successful approval of several new products including Targocid, Nicoderm, Cardizem CD and Seldane-D . "We are pleased that Peter has agreed to join D-Pharm," commented Dr. Alex Kozak, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of D-Pharm. "He brings a wealth of international experience working with both big pharma and biotech companies. Peter's proven track record in bringing new pharmaceuticals to global markets and in guiding the growth of an emerging pharmaceutical company will make an important contribution to D-Pharm." D-Pharm's drug development program is based on its proprietary RAP (Regulated Activation of Prodrugs) technology platform which enables drugs to be activated only within the cells affected by disease, substantially diminishing the adverse reactions adverse reactions, n.pl unfavorable reactions resulting from administration of a local anesthetic; responsible factors include the drug used, concentration, and route of administration. caused when drugs also activate within healthy cells. The company is applying RAP to improve drugs for the treatment of epilepsy, cardiac ischemia, stroke, inflammation and cancer. In addition, D-Pharm is developing DP-16, a novel neuroprotective agent neuroprotective agent Neurology Any agent or drug that protects the brain from secondary injury caused by stroke. See Stroke. for the treatment and prophylaxis prophylaxis (prō'fĭlăk`sĭs), measures designed to prevent the occurrence of disease or its dissemination. Some examples of prophylaxis are immunization against serious diseases such as smallpox or diphtheria; quarantine to confine of ischemia-reperfusion damage in stroke, head trauma and open-heart surgery. D-Pharm is a biopharmaceutical company developing proprietary drugs using rational drug design, delivery and targeting technologies. The company is based in the Kiryat Weizmann Science Park, Rehovot, Israel. CONTACT: D-Pharm Ltd. Dr. Alex Kozak or Dr. Yaffa Beck, 972-8-9300794 dpharm@netvision.net.il |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion